The significance of PD-L1 expression in resected lung adenocarcinoma
Lung adenocarcinoma (AD) is a common variant of lung cancer.Programmed cell death 1 /Programmed cell death ligand 1(PD1/PD-L1) is a promising immunotherapy target which has achieved promising results in advanced NSCLC patients in the ongoing clinical trials,and PD-L1 expression may be an important biomarker of predicting clinical response.In this study,we will evaluate PD-L1 expression and analyze its expression with the clinic pathological characteristics and outcomes in 133 cases of resected lung adenocarcinoma.Protein expression of PD-L1 was examined by immunohistochemistry method using the VENTANA PD-L1 (SP263) rabbit monoclonal antibody.Messenger RNA level of PD-L1 was evaluated by in situ hybridization method.PD-L1 expression rate in lung AD is 16.5% at the mRNA level and 13.5% at the protein level,which the kappa coefficient of the two examination methods is 0.824 (P=0.219,highly correlated).PD-L1 expression in lung AD was found to highly expressed in male patients and smokers (P=0.019 and 0.002),while no association were identified between PD-L1 expression and age,tumor size,clinical stage,positive pleural invasion,lymph node metastasis or therapy methods.Overexpression of PD-L1 was a significant indicator of shorter recurrence free survival time and overall survival (P=0.000 and 0.000).Multivariate analysis revealed that PD-L1 expression was an independent risk factor for poor RFS and overall survival (P=0.009 and 0.016).PD-L1 overexpression is more frequently observed in male patients and smokers in lung adenocarcinoma.PD-L1 expression is an indicator of worse prognosis in surgically resected lung adenocarcinoma patients.
Lung adenocarcinoma Programmed cell death ligand 1 Immunohistochemistry In situ hybridization
Shafei Wu Xiaohua Shi Jian Sun Yuanyuan Liu Yufeng Luo Zhiyong Liang Jinghui Wang Xuan Zeng
Department of pathology, Peking Union Medical College Hospital, Beijing, China Department of medical oncology, Beijing Thoracic Tumor and Tuberculosis Research Institute, Beijing
国内会议
2017年北京市第六届病理技术学术年会暨中国病理装备分会病理装备应用研讨会
北京
英文
218-227
2017-12-08（万方平台首次上网日期，不代表论文的发表时间）